BridgeMD
Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation (CodeBreaK 300)
EU CTIS ID: 2024-511187-81-00
What this study is testing
To compare progressionfree survival (PFS) in previously treated subjects with KRAS p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator’s choice (trifluridine and tipiracil or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator’s choice (trifluridine and tipiracil or regorafenib)
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.
- Fridericia's Correction Formula (QTcF) ≤ 470 msec
- Ability to take oral medications and willing to record daily adherence to investigational product.
- Age ≥ 18 years.
- Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation as determined by prospective central testing, using the analytically validated Qiagen Therascreen KRAS RGQ polymerase chain reaction (PCR) kit in CRC as an investigational device demonstrating a KRAS p.G12C mutation is present. Local testing and documentation of KRAS p.G12C mutation should have been previously performed as part of standard of care.
- Subjects will have received at least 1 prior line of therapy for metastatic disease. Subjects must have received and progressed or experienced disease recurrence on or after fluoropyrimidine, irinotecan, and oxaliplatin given for metastatic disease unless the subject, in the opinion of the investigator, is not a candidate for fluoropyrimidine, irinotecan, or oxaliplatin, in which case, the subject may be eligible after investigator discussion with Amgen medical monitor provided subject has received at least one prior line of therapy for metastatic disease and provided trifluridine and tipiracil or regorafenib is deemed the appropriate next line of therapy for the subject. Notes: Subjects with tumors known to be MSI-H must have received prior checkpoint inhibitor therapy if available in the region unless there is a medical contraindication, in which case, the subject may be eligible after investigator discussion with Amgen medical monitor. Subjects with tumors known to have BRAF V600E mutation must have received prior treatment with encorafenib and cetuximab if available for this indication in the country or region unless there is a medical contraindication in the opinion of the investigator, in which case the subject may be eligible for the trial after investigator discussion with and approval of the Amgen medical monitor. Adjuvant therapy will count as a line of therapy for metastatic disease if the subject progressed on or within six months of completion of adjuvant therapy administration. Maintenance therapy is not considered as a separate regimen of therapy. Adjuvant therapy given after resection of metastatic disease counts as a line of therapy for metastatic disease. Perioperative chemotherapy with or without chemoradiation in the metastatic setting will count as one line of therapy for metastatic disease if that was part of a multidisciplinary treatment plan for surgery.
You likely can't join if
- Active brain metastases. Subjects who have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to study day 1 are eligible
- Known history of human immunodeficiency virus infection
- Exclusion of hepatitis infection based on the following results and/or criteria: a)Positive hepatitis B surface antigen b)Negative HepBsAg with a positive for hepatitis B core antibody c)Positive Hepatitis C virus antibody: Hepatitis C virus RNA by polymerase chain reaction is necessary. Detectable Hepatitis C virus RNA renders the subject ineligible. If above antibody/antigen testing is not able to be obtained, positive hepatitis B or C viral load
- Subjects have received both trifluridine and tipiracil and regorafenib in the past
- Unresolved toxicities from prior anti-tumor therapy
- Previous treatment with a KRAS G12C inhibitor
See the full eligibility criteria
Who can join
- Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.
- Fridericia's Correction Formula (QTcF) ≤ 470 msec
- Ability to take oral medications and willing to record daily adherence to investigational product.
- Age ≥ 18 years.
- Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation as determined by prospective central testing, using the analytically validated Qiagen Therascreen KRAS RGQ polymerase chain reaction (PCR) kit in CRC as an investigational device demonstrating a KRAS p.G12C mutation is present. Local testing and documentation of KRAS p.G12C mutation should have been previously performed as part of standard of care.
- Subjects will have received at least 1 prior line of therapy for metastatic disease. Subjects must have received and progressed or experienced disease recurrence on or after fluoropyrimidine, irinotecan, and oxaliplatin given for metastatic disease unless the subject, in the opinion of the investigator, is not a candidate for fluoropyrimidine, irinotecan, or oxaliplatin, in which case, the subject may be eligible after investigator discussion with Amgen medical monitor provided subject has received at least one prior line of therapy for metastatic disease and provided trifluridine and tipiracil or regorafenib is deemed the appropriate next line of therapy for the subject. Notes: Subjects with tumors known to be MSI-H must have received prior checkpoint inhibitor therapy if available in the region unless there is a medical contraindication, in which case, the subject may be eligible after investigator discussion with Amgen medical monitor. Subjects with tumors known to have BRAF V600E mutation must have received prior treatment with encorafenib and cetuximab if available for this indication in the country or region unless there is a medical contraindication in the opinion of the investigator, in which case the subject may be eligible for the trial after investigator discussion with and approval of the Amgen medical monitor. Adjuvant therapy will count as a line of therapy for metastatic disease if the subject progressed on or within six months of completion of adjuvant therapy administration. Maintenance therapy is not considered as a separate regimen of therapy. Adjuvant therapy given after resection of metastatic disease counts as a line of therapy for metastatic disease. Perioperative chemotherapy with or without chemoradiation in the metastatic setting will count as one line of therapy for metastatic disease if that was part of a multidisciplinary treatment plan for surgery.
- Subjects must be willing to provide archived tumor tissue samples (formalin-fixed paraffin-embedded [FFPE] sample collected within 5 years) or agree to undergo a pretreatment tumor biopsy (excisional or core biopsy) prior to enrollment.
- Measurable disease per RECIST 1.1 criteria. Lesions previously radiated are not considered measurable unless they have progressed after radiation.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
- Life expectancy of > 3 months, in the opinion of the investigator
- Adequate hematologic and end-organ function, defined as the following within 2 weeks prior to cycle 1 day 1: Absolute neutrophil count (ANC) ≥ 1.5 x 109 /L (without granulocyte colony-stimulating factor support within 2 weeks of laboratory test used to determine eligibility) Hemoglobin ≥ 9.0 g/dL (without transfusion within 2 weeks of laboratory test used to determine eligibility) Platelet count ≥ 100 x 109 /L (without transfusion within 2 weeks of laboratory test used to determine eligibility) Aspartate aminotransferase (AST) and ALT ≤ 2.5 times the upper limit of normal (ULN) Serum bilirubin ≤ 1.0 x ULN. For subjects with Gilbert’s disease, total bilirubin or direct bilirubin needs to be ≤ 1.0 x ULN International normalized ratio (INR) and activated partial thromboplastin time (or partial thromboplastin time) ≤ 1.5 x ULN. Prothrombin time (PT) ≤ 1.5 x ULN may be used instead of INR for sites whose labs do not report INR Estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation ≥ 30 mL/min/1.73 m2
What rules you out
- Active brain metastases. Subjects who have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to study day 1 are eligible
- Known history of human immunodeficiency virus infection
- Exclusion of hepatitis infection based on the following results and/or criteria: a)Positive hepatitis B surface antigen b)Negative HepBsAg with a positive for hepatitis B core antibody c)Positive Hepatitis C virus antibody: Hepatitis C virus RNA by polymerase chain reaction is necessary. Detectable Hepatitis C virus RNA renders the subject ineligible. If above antibody/antigen testing is not able to be obtained, positive hepatitis B or C viral load
- Subjects have received both trifluridine and tipiracil and regorafenib in the past
- Unresolved toxicities from prior anti-tumor therapy
- Previous treatment with a KRAS G12C inhibitor
- Prior treatment with trifluridine and tipiracil in those subjects where investigator's choice would be trifluridine and tipiracil
- Prior treatment with regorafenib in those subjects where investigator's choice would be regorafenib
- Therapeutic or palliative radiation therapy within 2 weeks of study day 1
- Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy [except for subjects with history of completely resected breast cancer with no active disease for over 3 years on long term adjuvant endocrine therapy], or investigational agent) within 4 weeks of study day 1; please note that bisphosphonates or anti-RANKL antibody therapy is allowed if needed for management of hypercalcemia or for prevention of skeletal events. Checkpoint inhibitor therapy within 6 weeks of study day 1 is also excluded
- Required dose reduction of panitumumab in the past for toxicity
- History or presence of hematological malignancies unless curatively treated with no evidence of disease 2 years
- Use of warfarin. Other anticoagulation may be allowed
- Use of known cytochrome P450 (CYP) 3A4 sensitive substrates and P-glycoprotein (P-gp) substrates (with a narrow therapeutic window), within 14 days or 5 half-lives of the drug or its major active metabolite, whichever is longer, prior to study day 1
- Use of strong inducers of CYP3A4 within 14 days or 5 half-lives prior to study day 1
- Where Investigator's choice is regorafenib: use of strong inhibitors of CYP3A4 (including herbal supplements such as Goldenseal) within 14 days or 5 half-lives (whichever is longer) or grapefruit juice or grapefruit containing products within 7 days prior to study day 1
- Therapeutic oral or IV antibiotics within 2 weeks prior to randomization
- History of other malignancy within the past 3 years, with exceptions specified in the protocol
- Leptomeningeal disease
- Significant GI disorder that results in significant malabsorption, requirement for IV alimentation, or inability to take oral medication
- History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis
- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 6 months prior to randomization, unstable arrhythmias or unstable angina
- Significant uncontrolled concomitant disease that could affect compliance with protocol procedures or interpretation of results or that pose a risk to subject safety
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures at a frequency greater than monthly.
The study team makes the final eligibility decision.
Where it's taking place
- Korea, Republic of
- Japan
- United Kingdom
- Australia
- United States
- Taiwan
- Mexico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Korea, Republic of; Japan; United Kingdom; Australia; United States; Taiwan and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.